Vascular Biogenics (STU:0VB) Dividend Yield %: 0.00% (As of Jul. 24, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Vascular Biogenics Dividend Yield %?

Vascular Biogenics STU:0VB 10 Dividend Yield % is 0.00% as of Jul. 24, 2026. GuruFocus rates STU:0VB with a GF Score™ of 10/100. The stock has 5 warning signs investors should review.

As of today (2026-07-24), the Trailing Annual Dividend Yield of Vascular Biogenics is 0.00%.

The historical rank and industry rank for Vascular Biogenics's Dividend Yield % or its related term are showing as below:

STU:0VB's Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.32
* Ranked among companies with meaningful Dividend Yield % only.

Vascular Biogenics's Dividend Payout Ratio for the three months ended in Jun. 2023 was 0.00.

As of today (2026-07-24), the Forward Dividend Yield % of Vascular Biogenics is 0.00%.

Vascular Biogenics's Dividends per Share for the three months ended in Jun. 2023 was €0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.


Vascular Biogenics  (STU:0VB) Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.


Vascular Biogenics Dividend Yield % Related Terms


Vascular Biogenics Dividend Yield % Historical Data

* Premium members only.

The historical data trend for Vascular Biogenics's Dividend Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vascular Biogenics Dividend Yield % Chart

Vascular Biogenics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Dividend Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Vascular Biogenics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Dividend Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

STU:0VB vs MBIO, GNPX, LEXX: Dividend Yield % Comparison

For the Biotechnology subindustry, Vascular Biogenics's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vascular Biogenics Dividend Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vascular Biogenics's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Vascular Biogenics's Dividend Yield % falls into.



Vascular Biogenics Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

Frequently Asked Questions Learn more about Dividend Yield % →
What does a Dividend Yield % of 0.00% mean?
Vascular Biogenics (STU:0VB) has a Dividend Yield % of 0.00% as of Jul. 24, 2026. Dividend yield is the ratio of company dividends to the share price. View historical data on Vascular Biogenics and its competitors.
Is Vascular Biogenics' Dividend Yield % too high?
Vascular Biogenics' current Dividend Yield % is 0.00%. Overall, Vascular Biogenics has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Vascular Biogenics' Dividend Yield % compare to MBIO and GNPX?
Vascular Biogenics' Dividend Yield % of 0.00% can be compared against companies in the Biotechnology industry. The industry median Dividend Yield % is 1.32. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Yield % for a Biotechnology company?
The median Dividend Yield % among Biotechnology companies is 1.32, based on 151 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Yield % mean?
A high Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Dividend yield is the ratio of company dividends to the share price. View historical data on Vascular Biogenics and its competitors. For the Biotechnology industry, the median Dividend Yield % is 1.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vascular Biogenics's current Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vascular Biogenics stock overvalued right now?
Vascular Biogenics (STU:0VB) has a current Dividend Yield % of 0.00%. The current Dividend Yield % is 0.00%. Vascular Biogenics' overall GF Score™ is 10/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Yield % calculated?
Dividend Yield % is calculated from a company's financial statements. For Vascular Biogenics (STU:0VB), the current Dividend Yield % is 0.00% as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vascular Biogenics Business Description

Address 8 HaSatat Street, Modi’in, ISR, 7178106
Vascular Biogenics Ltd is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of first-in-class treatments for cancer. The lead product candidate of the company is VB-111 which is a gene-based biologic which is being developed for solid tumor indications for recurrent glioblastoma, an aggressive form of brain cancer. The company is also engaged in conducting a program targeting anti-inflammatory diseases, based on the use of Lecinoxoid platform technology. The product brands of the company include VTS, Vascular Targeting Systems, Vbl, Vascular Biogenics And Vascular Therapeutics.